Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
JAZZ - Jazz Pharmaceuticals plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$293.00
DETAILS
HIGH:
$337.00
LOW:
$229.00
MEDIAN:
$300.00
CONSENSUS:
$293.00
UPSIDE:
26.74%
Stock News
Financial Comparison: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. vTv Therapeutics (NASDAQ:VTVT)
Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and vTv Therapeutics (NASDAQ: VTVT - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Analyst Ratings This is a summary of current
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
Jazz Pharmaceuticals (NASDAQ: JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Ziihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
Jazz Pharmaceuticals (NASDAQ: JAZZ) executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference. Chumi Khurana, senior vice president of U.S. Oncology Franchise, said Jazz's oncology business grew revenue 32% year over year and crossed the $1 billion mark in 2025. She
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Get Jazz Pharmaceuticals alerts:Sign UpZiihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically significant overall-survival result for its zanidatamab-plus-chemotherapy arm versus a control arm in a second interim analysis.
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
Jazz paid $820 million up front to acquire Actio Biosciences. Actio shareholders could receive another $500 million in milestone payments.
Engineers Gate Manager LP Reduces Stock Position in Jazz Pharmaceuticals PLC $JAZZ
Engineers Gate Manager LP cut its holdings in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 93.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,287 shares of the specialty pharmaceutical company's stock after selling 86,703 shares
Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy Transaction strengthens Jazz's epilepsy pipeline and reinforces its commitment to advance treatment options in rare disease DUBLIN, Sept. 15, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. ("Actio") for $820 million upfront.
Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 1:30 p.m.
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
JAZZ Rises on Updated OS Results From Gastric Cancer Study
Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backbone therapy in first-line GEA Longer follow up of Ziihera plus tislelizumab and chemotherapy shows improved OS hazard ratio, further supporting this regimen as the new standard of care Data submitted for presentation in fourth quarter 2026 For U.S. media and investors only DUBLIN, Aug. 31, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial showing that Ziihera® (zanidatamab-hrii) in combination with chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS compared with trastuzumab plus chemotherapy as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The Ziihera plus chemotherapy OS hazard ratio improved compared with the first interim analysis.
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA
Jazz Pharmaceuticals (NASDAQ: JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma, or GEA. Ziihera, or zanidatamab, is approved in combination with tislelizumab and fluoropyrimidine- and platinum-containing chemotherapy for patients whose tumors are HER2 IHC 3+ or IHC 2+
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of $1.0 billion aggregate principal amount of notes.
Price Targets
Jazz Pharmaceuticals price target raised to $286 from $281 at Truist
$286.00
(was $233.50)
Truist Financial
Jazz Pharmaceuticals resumed with a Buy at Goldman Sachs
$337.00
(was $234.88)
Goldman Sachs
Jazz Pharmaceuticals price target raised to $337 from $315 at UBS
$337.00
(was $245.35)
UBS
Jazz Pharmaceuticals price target raised to $271 from $270 at Barclays
$271.00
(was $241.31)
Barclays
Jazz Pharmaceuticals price target raised to $299 from $277 at RBC Capital
$299.00
(was $247.45)
Leonid Timashev
·
RBC Capital
Jazz Pharmaceuticals (JAZZ) PT Raised to $277 at RBC Capital
$277.00
(was $257.54)
Leonid Timashev
·
RBC Capital
Jazz Pharmaceuticals price target raised to $281 from $264 at Truist
$281.00
(was $257.04)
Gregory Renza
·
Truist Financial
Jazz Pharmaceuticals price target raised to $322 from $283 at Morgan Stanley
$322.00
(was $257.52)
Morgan Stanley
Jazz Pharmaceuticals price target raised to $310 from $292 at Needham
$310.00
(was $260.23)
Needham
Canaccord Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
$300.00
(was $260.23)
Gary Newman
·
Canaccord Genuity
Jazz Pharmaceuticals (JAZZ) PT Raised to $300 at Deutsche Bank
$300.00
(was $260.23)
David Hoang
·
Deutsche Bank
Jazz Pharmaceuticals price target raised to $283 from $280 at Morgan Stanley
$283.00
(was $252.19)
Morgan Stanley
Jazz Pharmaceuticals price target raised to $287 from $270 at Deutsche Bank
$287.00
(was $252.56)
Deutsche Bank
Jazz Pharmaceuticals (JAZZ) PT Raised at TD Cowen Following 'Nice Topline Beat And Raise'
$300.00
(was $250.22)
Truist Financial
Jazz Pharmaceuticals price target raised to $280 from $245 at Morgan Stanley
$280.00
(was $255.41)
Morgan Stanley
Jazz Pharmaceuticals price target raised to $264 from $254 at Truist
$264.00
(was $251.58)
Truist Financial
Jazz Pharmaceuticals (JAZZ) PT Raised to $292 at Needham
$292.00
(was $251.58)
Ami Fadia
·
Needham
Jazz Pharmaceuticals price target raised to $315 from $307 at UBS
$315.00
(was $251.58)
UBS
Jazz Pharmaceuticals price target raised to $300 from $285 at Wells Fargo
$300.00
(was $251.58)
Wells Fargo
Jazz Pharmaceuticals price target raised to $275 from $230 at Stifel
$275.00
(was $251.58)
Stifel Nicolaus